Does SLNB substitute END in the future with the sole advantage of preventing shoulder morbidity?
Head and neck neoplasms
Lymph nodes
Neck dissection
Oral cancer
Sentinel lymph node biopsy
Squamous cell carcinoma
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
08
11
2021
accepted:
09
11
2021
pubmed:
20
11
2021
medline:
11
3
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
SLNB has emerged as a rational proposition in the management of early-stage oral cancer and has mixed responses within the oncological community. It is high time for the clinicians to look into the fact that, when a patient post-surgery has a regional recurrence within 6 months, it could be reasonable to believe that a tumor seed which was earlier an isolated tumor cell (ITC) or in the form of a micro-metastasis (MM) would have led to this. SLNB has the potential to become a standard of care in the future owing to the development and utility of better evaluation tools to pick nodal metastasis. It is not an overemphasizing statement to say that SLNB could become a standard recommendation in the near future, however, it still looks like a distant dream considering its logistical and technological limitations.
Identifiants
pubmed: 34798576
pii: S1368-8375(21)00735-1
doi: 10.1016/j.oraloncology.2021.105628
pii:
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
105628Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.